CN100409848C - 一种稳定的氢溴酸高乌甲素冻干粉针剂及其制备方法 - Google Patents
一种稳定的氢溴酸高乌甲素冻干粉针剂及其制备方法 Download PDFInfo
- Publication number
- CN100409848C CN100409848C CNB2004100596726A CN200410059672A CN100409848C CN 100409848 C CN100409848 C CN 100409848C CN B2004100596726 A CNB2004100596726 A CN B2004100596726A CN 200410059672 A CN200410059672 A CN 200410059672A CN 100409848 C CN100409848 C CN 100409848C
- Authority
- CN
- China
- Prior art keywords
- freeze
- dried powder
- lappaconitine hydrobromide
- preparation
- hydrobromide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000843 powder Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims description 21
- 238000004108 freeze drying Methods 0.000 title claims description 9
- 238000002347 injection Methods 0.000 title abstract description 10
- 239000007924 injection Substances 0.000 title abstract description 10
- 239000000243 solution Substances 0.000 title description 10
- CFFYROOPXPKMEQ-OPLXFBIMSA-N lappaconite hydrobromide Chemical compound Br.O([C@]12CN(C3[C@H]4[C@]5(O)[C@@]6(O)[C@@H](OC)[C@@H]([C@H](C5)OC)C[C@H]6[C@@]3([C@@H]1C4)[C@@H](OC)CC2)CC)C(=O)C1=CC=CC=C1NC(C)=O CFFYROOPXPKMEQ-OPLXFBIMSA-N 0.000 title 1
- QUSPUZQKMRMVFL-UHFFFAOYSA-N 2-(benzenesulfonamido)-4-methylsulfanylbutanoic acid Chemical compound CSCCC(C(O)=O)NS(=O)(=O)C1=CC=CC=C1 QUSPUZQKMRMVFL-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 235000010265 sodium sulphite Nutrition 0.000 claims description 6
- 238000000859 sublimation Methods 0.000 claims description 6
- 230000008022 sublimation Effects 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 238000010792 warming Methods 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 2
- 235000010352 sodium erythorbate Nutrition 0.000 claims description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000001914 filtration Methods 0.000 description 8
- 238000012856 packing Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000012982 microporous membrane Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- 241001586439 Aconitum sinomontanum Species 0.000 description 1
- AJHOMRPUITXELY-KFRFWBOGSA-N C1[C@@H]2C[C@@H]3[C@]1([C@](CC2)([C@H]2C[C@@H]1[C@]4(CCC[C@@]31[C@@H]2NC4)O)O)O Chemical compound C1[C@@H]2C[C@@H]3[C@]1([C@](CC2)([C@H]2C[C@@H]1[C@]4(CCC[C@@]31[C@@H]2NC4)O)O)O AJHOMRPUITXELY-KFRFWBOGSA-N 0.000 description 1
- 241000205571 Caulophyllum Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
预冻阶段降温时间 | 复水时间(s) |
20分钟 | 12 |
40分钟 | 20 |
1小时 | 22 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100596726A CN100409848C (zh) | 2003-06-24 | 2004-06-16 | 一种稳定的氢溴酸高乌甲素冻干粉针剂及其制备方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN03146759.8 | 2003-06-24 | ||
CN03146759 | 2003-06-24 | ||
CNB2004100596726A CN100409848C (zh) | 2003-06-24 | 2004-06-16 | 一种稳定的氢溴酸高乌甲素冻干粉针剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1600309A CN1600309A (zh) | 2005-03-30 |
CN100409848C true CN100409848C (zh) | 2008-08-13 |
Family
ID=34679654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100596726A Expired - Lifetime CN100409848C (zh) | 2003-06-24 | 2004-06-16 | 一种稳定的氢溴酸高乌甲素冻干粉针剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100409848C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102525896B (zh) * | 2011-01-12 | 2013-08-28 | 北京人福军威医药技术开发有限公司 | 氢溴酸高乌甲素的药物组合物 |
CN104688693B (zh) * | 2015-03-23 | 2017-04-26 | 山东北大高科华泰制药有限公司 | 注射用氢溴酸高乌甲素粉针剂药物组合物和制法 |
CN108997216B (zh) * | 2018-07-20 | 2020-10-30 | 西安惠博生物科技有限公司 | 高乌甲素晶体、制备方法、高乌甲素冻干粉针及制备方法 |
-
2004
- 2004-06-16 CN CNB2004100596726A patent/CN100409848C/zh not_active Expired - Lifetime
Non-Patent Citations (5)
Title |
---|
HPLC法测定氢溴酸高乌甲素注射液的含量. 吕毅.药物分析杂志,第21卷第5期. 2001 |
HPLC法测定氢溴酸高乌甲素注射液的含量. 吕毅.药物分析杂志,第21卷第5期. 2001 * |
药剂学. 毕殿洲 主编,241页表9-1,人民卫生出版社. 1999 药剂学. 毕殿洲 主编,268页(1)部分,人民卫生出版社. 1999 |
药剂学. 毕殿洲 主编,241页表9-1,人民卫生出版社. 1999 * |
药剂学. 毕殿洲 主编,268页(1)部分,人民卫生出版社. 1999 * |
Also Published As
Publication number | Publication date |
---|---|
CN1600309A (zh) | 2005-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI107701B (fi) | Menetelmä parannettujen kylmäkuivattujen ifosfamidikoostumuksien valmistamiseksi | |
WO2001041800A9 (en) | Compositions and methods for stabilizing biological molecules upon lyophilization | |
EP1660073A2 (en) | Hydrophobic drug compositions containing reconstitution enhancer | |
EP0318146B1 (en) | Antibiotic solutions and the lyophilization thereof | |
KR950702424A (ko) | 결정형 아미포스틴 조성물과 그 제조방법 또한 그 용도(Crystalline amifostine compositions and methods for the preparation and use of same) | |
EP3218061A1 (en) | Carmustine pharmaceutical composition | |
WO2022029303A1 (en) | Lyophilisation process | |
CN100409848C (zh) | 一种稳定的氢溴酸高乌甲素冻干粉针剂及其制备方法 | |
US4146971A (en) | Method of preparing a rapidly dissolving powder of sterile crystalline cefazolin sodium for parenteral administration | |
CN1046516C (zh) | 化合物dx-52-1的稳定方法和其冻干组合物 | |
US10149857B2 (en) | Lyophilized cyclophosphamide composition and methods of preparation thereof | |
US20110144147A1 (en) | Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity | |
US5972912A (en) | Method for lyophilizing ifosfamide | |
RU2225709C2 (ru) | Лиофилизат с улучшенной восстанавливаемостью в исходное состояние (варианты), способ его получения и фармацевтический препарат | |
CN112691083B (zh) | 盐酸万古霉素的冻干工艺 | |
US7323572B2 (en) | Process for controlling the hydrate mix of a compound | |
EP4070785B1 (en) | Lyophilized composition of copanlisib salt | |
JP2988631B2 (ja) | ホスホマイシンナトリウムの凍結乾燥製剤およびその製造法 | |
JPH0466202B2 (zh) | ||
CZ309689A3 (en) | Process for preparing dry injections of cis-diaminedichloroplatinum complex | |
MXPA05000721A (es) | Procedimiento para controlar la mezcla de hidratos de un compuesto. | |
FI68055C (fi) | Foerfarande foer framstaellning av ett snabbloesligt pulver avristallint cefalotinnatrium | |
FI67855C (fi) | Foerfarande foer framstaellning av ett vaesentligen kristallint laettloeslig cefazolinnatrium | |
IE45353B1 (en) | A procress for preparing solid sodium amoxycillin | |
JP2004269541A (ja) | デキストラン類の凍結乾燥方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: GUANGDONG BADA PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: BADA PHARMACEUTICAL CO., LTD., SHANTOU CITY |
|
CP01 | Change in the name or title of a patent holder |
Address after: 515100, Shantou, Chaoyang District, Guangdong, Guang Shan highway, West Rock, Shanxi side Patentee after: GUANGDONG BADA PHARMACEUTICAL Co.,Ltd. Address before: 515100, Shantou, Chaoyang District, Guangdong, Guang Shan highway, West Rock, Shanxi side Patentee before: Shantou Bada Pharmaceutical Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: ZHONGSHENG PHARMACEUTICAL CO., LTD., GUANGDONG Free format text: FORMER OWNER: GUANGDONG BADA PHARMACEUTICAL CO., LTD. Effective date: 20140117 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 515100 SHANTOU, GUANGDONG PROVINCE TO: 523326 DONGGUAN, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140117 Address after: 523326 Information Industry Park, Shilong Industrial Zone, Shilong Town, Dongguan, Guangdong, West Lake Patentee after: GUANGDONG ZHONGSHENG PHARMACEUTICAL Co.,Ltd. Address before: 515100, Shantou, Chaoyang District, Guangdong, Guang Shan highway, West Rock, Shanxi side Patentee before: GUANGDONG BADA PHARMACEUTICAL Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20080813 |
|
CX01 | Expiry of patent term |